Sentiment Change Report: Five Prime Therapeutics Inc (NASDAQ:FPRX)

Sentiment for Five Prime Therapeutics Inc (NASDAQ:FPRX)

Five Prime Therapeutics Inc (NASDAQ:FPRX) institutional sentiment increased to 1.58 in Q1 2019. Its up 0.38, from 1.2 in 2018Q4. The ratio is better, as 52 funds opened new or increased holdings, while 33 sold and decreased their stock positions in Five Prime Therapeutics Inc. The funds in our partner’s database now hold: 30.55 million shares, up from 29.49 million shares in 2018Q4. Also, the number of funds holding Five Prime Therapeutics Inc in their top 10 holdings was flat from 1 to 1 for the same number . Sold All: 11 Reduced: 22 Increased: 35 New Position: 17.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $204.11 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

The stock decreased 0.35% or $0.02 during the last trading session, reaching $5.66. About 271,931 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 48.45% since July 14, 2018 and is downtrending. It has underperformed by 52.88% the S&P500.

Analysts await Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report earnings on August, 14. They expect $-0.86 earnings per share, up 13.13 % or $0.13 from last year’s $-0.99 per share. After $-1.02 actual earnings per share reported by Five Prime Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -15.69 % EPS growth.

Bvf Inc Il holds 4.6% of its portfolio in Five Prime Therapeutics, Inc. for 3.06 million shares. Great Point Partners Llc owns 2.40 million shares or 3.18% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.26% invested in the company for 505,000 shares. The New York-based Armistice Capital Llc has invested 0.22% in the stock. Hilltop Holdings Inc., a Texas-based fund reported 33,337 shares.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Ratings Coverage

Ratings analysis reveals 100% of Five Prime Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Five Prime Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. FPRX was included in 5 notes of analysts from January 17, 2019. The stock has “Outperform” rating by Wedbush on Thursday, January 17.

More notable recent Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news were published by: which released: “The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer – Benzinga” on June 04, 2019, also with their article: “MiMedx Group and ARCA biopharma among healthcare gainers; Stellar Biotechnologies and Aduro BioTech among losers – Seeking Alpha” published on June 03, 2019, published: “Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors – Business Wire” on May 15, 2019. More interesting news about Five Prime Therapeutics, Inc. (NASDAQ:FPRX) were released by: and their article: “Wall Street Brunch – Seeking Alpha” published on June 16, 2019 as well as‘s news article titled: “Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue? –” with publication date: January 24, 2019.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.